What is HC Wainwright’s Forecast for PSTV FY2029 Earnings?

Plus Therapeutics, Inc. (NASDAQ:PSTV) – Investment analysts at HC Wainwright issued their FY2029 earnings estimates for Plus Therapeutics in a report issued on Friday, March 28th. HC Wainwright analyst S. Lee expects that the company will post earnings of $0.95 per share for the year. HC Wainwright currently has a “Buy” rating and a $5.50 price target on the stock. The consensus estimate for Plus Therapeutics’ current full-year earnings is ($2.30) per share.

Plus Therapeutics (NASDAQ:PSTV) last issued its earnings results on Thursday, March 27th. The company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.16). The business had revenue of $1.80 million during the quarter, compared to analyst estimates of $1.19 million.

Several other research firms also recently weighed in on PSTV. Ascendiant Capital Markets reduced their target price on shares of Plus Therapeutics from $20.00 to $19.00 and set a “buy” rating for the company in a research note on Monday, December 9th. D. Boral Capital restated a “buy” rating and issued a $9.00 target price on shares of Plus Therapeutics in a research note on Friday, March 28th.

Plus Therapeutics Trading Up 7.4 %

NASDAQ PSTV opened at $1.02 on Monday. The business has a fifty day simple moving average of $1.10 and a 200 day simple moving average of $1.23. Plus Therapeutics has a 12 month low of $0.24 and a 12 month high of $2.67. The firm has a market capitalization of $6.01 million, a P/E ratio of -0.40 and a beta of 0.73.

About Plus Therapeutics

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.